Priess D and colleagues from BHF Glasgow Cardiovascular Research Centre, University of Glasgow, United Kingdom conducted a meta-analysis to investigate whether intensive-dose statin therapy is associated with increased risk of new-onset diabetes compared with moderate-dose statin therapy. They included all randomized controlled end-point trials (January 1, 1996, through March 31, 2011) that compared intensive-dose statin therapy with moderate-dose statin therapy and had more than 1000 participants with > 1 year follow-up.
They found that in 5 statin trials with 32 752 participants without diabetes at baseline, 2749 developed diabetes (2.0 additional cases in the intensive-dose group per 1000 patient-years) and 6684 experienced cardiovascular events (6.5 fewer cases in the intensive-dose group per 1000 patient-years) over a weighted mean (SD) follow-up of 4.9 (1.9) years. Odds ratios were 1.12 for new-onset diabetes and 0.84 for cardiovascular events for participants receiving intensive therapy compared with moderate-dose therapy.
The authors concluded that in a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dose statin therapy.
No comments:
Post a Comment